The role of menopausal hormone therapy in the prevention of type 2 diabetes melltus in postmenopausal women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The incidence of type 2 diabetes mellitus (DM2) is constantly increasing worldwide, becoming a significant health problem due to the higher risk of cardiovascular complications associated with this disease. A better understanding of the DM2 pathophysiology in postmenopausal women may change prevention strategies and improve treatment outcomes. The role of menopausal hormone therapy in the prevention of DM2 is not fully understood, mainly due to the lack of sufficient results from randomized clinical trials; the available data, however, indicate a significant reduction in the risk of newly diagnosed DM2 in patients receiving this therapy.

Full Text

Restricted Access

About the authors

Sergey S. Apetov

Endocrine Health Center

Email: apetov@rambler.ru
Cand. Sci. (Med.), Endocrinologist, Obstetrician-Gynecologist Chelyabinsk, Russia

V. V Apetova

Endocrine Health Center

Chelyabinsk, Russia

References

  1. The IDF Diabetes Atlas 10th edition, 2021. URL: https://diabetesatlas.org/atlas/tenth-edition/.
  2. Dedov I., Shestakova M, Benedetti M.M., et al. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90-5. doi: 10.1016/j.diabres.2016.02.010.
  3. Barbiellini Amidei C, Fayosse A., Dumurgier J., et al. Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. JAMA. 2021;325(16):1640-49. Doi: 10.1001/ jama.2021.4001.
  4. URL: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
  5. Narayan K.M., Boyle J.P, Thompson TJ., et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884-90. doi: 10.1001/jama.290.14.1884.
  6. Sattar N, Rawshani A., Franzen S., et al. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation. 2019;139(19):2228-37. doi: 10.1161/GRCULATI0NAHA.118.037885.
  7. Elks C.E, Ong K.K., Scott R.A., et al. Ageatmenarche and type 2 diabetes risk: the EPIC-InterAct study. Diabetes Care. 2013;36(11):3526-34. doi: 10.2337/dc13-0446.
  8. Anagnostis P., Paparodis R.D., Bosdou J.K., et al. Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies. Endocrine. 2021;74(2):245-53. doi: 10.1007/s12020-021-02801-2.
  9. Dennison R.A., Chen E.S., Green M.E., et al. The absolute and relative risk of type 2 diabetes after gestational diabetes: A systematic review and meta-analysis of 129 studies. Diabetes Res Clin Pract. 2021;171:108625. Doi: 10.1016/j. diabres.2020.108625.
  10. Li P, Shan Z., Zhou L., et al. MECHANISMS IN ENDOCRINOLOGY: Parity and risk of type 2 diabetes: a systematic review and dose-response meta-analysis. Eur J Endocrinol. 2016;175(5):R231-45. doi: 10.1530/EJE-16-0321.
  11. Tobias D.K., Gaskins A.J., Missmer S.A., et al. History of infertility and risk of type 2 diabetes mellitus: a prospective cohort study. Diabetologia. 2015;58(4):707-15. doi: 10.1007/s00125-015-3493-z.
  12. Ye F, Wen J., Yang A., et al. The Influence of Hormone Therapy on secondary diabetes mellitus in Breast Cancer: A Meta-analysis. Clin Breast Cancer. 2022 Jan;22(1):e48-e58. doi: 10.1016/j.clbc.2021.06.014.
  13. Stepaniak U., Szafraniec K., Kubinova R., et al. Age at natural menopause in three central and eastern European urban populations: the HAPIEE study. Maturitas. 2013;75(1):87-93. Doi:10.1016/j. maturitas.2013.02.008.
  14. Paschou S.A., Anagnostis P., Pavlou D.I., et al. Diabetes in Menopause: Risks and Management. Curr Vasc Pharmacol. 2019;17(6):556-63. doi: 10.2174/1570161116666180625124405.
  15. Sun P., Wen H, Liu X., et al. Time trends in type 2 diabetes mellitus incidence across the BRiCS from 1990 to 2019: an age-period-cohort analysis. BMC Public Health. 2022;22(1):65. doi: 10.1186/s12889-021-12485-y.
  16. Ren Y, Zhang M, Liu Y., et al. Association of menopause and type 2 diabetes mellitus. Menopause. 2019;26(3):325-330. doi: 10.1097/GME.0000000000001200.
  17. Brand J.S., van der Schouw Y.T., Onland-Moret N.C., et al. Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study. Diabetes Care. 2013;36(4):1012-19. doi: 10.2337/dc12-1020.
  18. Muka T., Asllanaj E., Avazverdi N., et al. Age at natural menopause and risk of type 2 diabetes: a prospective cohort study. Diabetologia. 2017;60(10):1951-60. doi: 10.1007/s00125- 017-4346-8.
  19. Anagnostis P., Christou K., Artzouchaltzi A.M., et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and metaanalysis. Eur J Endocrinol. 2019;180(1):41-50. doi: 10.1530/EJE-18-0602.
  20. Janssen I., Powell L.H., Crawford S., et al. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med. 2008;168(14):1568-75. doi: 10.1001/archinte.168.14.1568.
  21. Koistinen H.A., Zierath J.R. Regulation of glucose transport in human skeletal muscle. Ann Med. 2002;34(6):410-8. doi: 10.1080/078538902321012351.
  22. Barros R.P, Gustafsson J.A. Estrogen receptors and the metabolic network. Cell Metab. 2011;14(3):289-99. Doi: 10.1016/j. cmet.2011.08.005.
  23. Geraci A, Calvani R, Ferri E, et al. Sarcopenia and Menopause: The Role of Estradiol. Front Endocrinol (Lausanne). 2021;12:682012. doi: 10.3389/fendo.2021.682012.
  24. Clegg D.J., Brown L.M., Woods S.C., et al. Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes. 2006;55(4):978-87. doi: 10.2337/diabetes.55.04.06.db05-1339. Erratum in: Diabetes. 2007 Oct;56(10):2649.
  25. Wohlers L.M., Spangenburg E.E. 17beta-estradiol supplementation attenuates ovariectomy-induced increases in ATGL signaling and reduced perilipin expression in visceral adipose tissue. J Cell Biochem. 2010;110(2):420-27. Doi: 10.1002/ jcb.22553.
  26. Zhao J, Wu Y, Rong X, et al. Anti-Lipolysis Induced by Insulin in Diverse Pathophysiologic Conditions of Adipose Tissue. Diabetes Metab Syndr Obes. 2020;13:1575-85. doi: 10.2147/DMSO. S250699.
  27. Yan H., Yang W., Zhou F., et al. Estrogen Improves Insulin Sensitivity and Suppresses Gluconeogenesis via the Transcription Factor Foxo1. Diabetes. 2019;68(2):291-304. doi: 10.2337/db18-0638.
  28. Jones M., Tett S., Peeters G.M., et al. New-Onset Diabetes After Statin Exposure in Elderly Women: The Australian Longitudinal Study on Women's Health. Drugs Aging. 2017;34(3):203-9. doi: 10.1007/s40266-017-0435-0.
  29. Nazarzadeh M., Bidel Z., Canoy D., et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data metaanalysis. Lancet.2021:398(10313):1803-10. doi: 10.1016/S0140-6736(21)01920-6.
  30. Baber R.J., Panay N., Fenton A. IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50. doi: 10.3109/13697137.2015.1129166.
  31. Manson JE, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol. 1992;2(5):665-73. doi: 10.1016/1047-2797(92)90011-e.
  32. Kapoor E., Kling J.M., Lobo A.S., et al. Menopausal hormone therapy in women with medical conditions. Best Pract Res Clin Endocrinol Metab. 20215(6):101578. Doi: 10.1016/j. beem.2021.101578.
  33. Kanaya A.M., Herrington D., Vittinghoff E., et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 2003;138(1):1-9. doi: 10.7326/0003-4819138-1-200301070-00005.
  34. Margolis K.L., Bonds D.E., Rodabough R.J., et al. Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004;47(7):1175-87. doi: 10.1007/s00125-004-1448-x.
  35. Manson J.E., Kaunitz A.M. Menopause Management-Getting Clinical Care Back on Track. N Engl J Med. 2016;374(9):803-6. doi: 10.1056/NEJMp1514242.
  36. Salpeter S.R., Walsh J.M., Ormiston T.M., et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538-54. doi: 10.1111/j.1463-1326.2005.00545. x.
  37. de Lauzon-Guillain B., Fournier A., Fabre A., et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Gene rale de l'Education Nationale (E3N) cohort. Diabetologia. 2009;52(10):2092-100. Doi: 10.1007/ s00125-009-1456-y.
  38. Rizzo M.R., Leo S., De Franciscis P., et al. Shortterm effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age (Dordr). 2 014;3 6( 1 ):2 65- 74. doi: 10.1007/s11357-013-9554-7.
  39. Vujovic S., Ivovic M., Tancic-Gajic M., et al. Effects of different menopause hormone therapy routes of administration on insulin levels in early menopausal non-diabetic subjects. Gyn Rep End Met. 2021;2(1):60-4.
  40. Papadakis G.E., Hans D., Gonzalez Rodriguez E., et al. Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort. J Clin Endocrinol Metab. 2018;103(5):1948-.5 7. Doi: 10.1210/ jc.2017-02449.
  41. Kim S.W., Kim R. The association between hormone therapy and sarcopenia in postmenopausal women: the Korea National Health and Nutrition Examination Survey, 20082011. Menopause. 2020;27(5):506-11. doi: 10.1097/GME.0000000000001509.
  42. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873.
  43. Garcia-Estevez L., Cortes J., Perez S., et al. Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status. Front Oncol. 2021;11:705911. Doi: 10.3389/ fonc.2021.705911.
  44. Boyle P., Boniol M., Koechlin A., et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 20123;107(9):1608-17. Doi: 10.1038/ bjc.2012.414.
  45. Hou N., Hong S., Wang W., et al. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18;105(18):1365-72. doi: 10.1093/jnci/ djt207.
  46. Suba Z. Circulatory estrogen level protects against breast cancer in obese women. Recent Pat Anticancer Drug Discov. 2013;8(2):154-67. doi: 10.2174/1574892811308020004
  47. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost. 2010 May;8(5):979-86. doi: 10.1111/j.1538-7836.2010. 03839.x.
  48. Hotoleanu C. Association between obesity and venous thromboembolism. Med Pharm Rep. 2020;93(2):162-68. doi: 10.15386/mpr-1372.
  49. Charlier S.H.R., Meier C., Jick, S.S. et al. Association between glycemic control and risk of venous thromboembolism in diabetic patients: a nested case-control study. Cardiovasc Diabetol. 2022;21(2). Doi.org/10.1186/s12933-021-01432-1.
  50. Canonico M., Oger E., Plu-Bureau G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-45. Doi: 10.1161/ CIRCULATIONAHA.106.642280.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies